Pulmonary delivery, of both individual nanoparticles and encapsulated within carrier particles, is attractive method in antitubercular therapy; however, literature reports of these system have not shown consistently successful results due to poor loading of the frontline drug and inefficient sustained release profile. Here, a multifaceted synthetic strategy is employed to prepare stimuli responsive polymeric nanocarrier, RCP-2, with high purity, reproducibility, and precisely controlled stoichiometry of the drug motifs to demonstrate the high drug content as well as controlled release in a systematic manner. The drug release profile of RCP-2 in mild acidic conditions implies the smart drug delivery nature of the nanocarrier. Cancerous cell lines, 4 T and A549, are employed due to their acidic nature to demonstrate the proposed pH responsive design. Surprisingly, the preliminary MTT assay against A549 cells (Lung cancer cell lines) shows a high anticancer efficacy. Taken together, these results demonstrate the significance of our unique design in which multi-frontline TB drugs are efficiently attached to produce the multi-task nanocarrier for potential therapeutic treatment.